|
⚲
|
| Keyboard |
| Adjuvant Capital LP
✚
|
|
|---|---|
| CRD # | 301716 |
| SEC # | 801-118403 |
| CIK # | 0001935084 |
| AUM | |
| Employees | 5 (80% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 917-334-0724 |
| Address | 500 5th Avenue New York, NY 10110 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2023) [Brochure] |
|---|
Fees and Compensation
A. As compensation for its services, Adjuvant receives an annual management fee (the “Management
Fee”) based on a fixed rate percentage of the Fund’s committed capital. The Management Fee is required to
be paid to the Firm even if the Fund experiences net losses in a particular year or over the term of the Fund.
Because there is a fixed investment period after which capital from Limited Partners can only be drawn down
in limited circumstances and because the Management Fees are, at certain times during the life of the Fund,
based upon capital invested by the Fund, this fee structure creates an incentive to deploy capital when the Firm
would not otherwise do so.
In addition, the General Partner is entitled to received incentive-based compensation (“Carried Interest”) based
on realized gains from investments.
For a schedule of the Management Fee and Carried Interest, please refer to the Fund’s Governing Documents.
B. The Firm receives the Management Fee directly from the Fund by deducting the applicable amounts
from the Fund’s assets.
C. Adjuvant and the Fund generally bear their own expenses. Expenses, above and beyond the
Management Fee and Carried Interest discussed above, are allocated on a case by case basis in accordance with
the Governing Documents. Additional expenses the Fund will incur generally include but are not limited to
Fund operating expenses and organizational expenses, which include:
(i) legal, Fund administration (including maintaining the books and records of the Fund,
including any related internal costs that the Firm may incur to produce any such books and
records or external costs for a third-party administrator to maintain and oversee the Fund’s
books and records), accounting, audit, consulting (including, but not limited to, consulting
fees incurred by the Fund for the benefit of a portfolio company), depository (including a
depository appointed pursuant to the Alternative Investment Fund Managers Directive),
investment banking, fees paid to third-party valuation agents for valuations, appraisals and
pricing services, reporting, research and other information (including data and information
service subscriptions, related systems and services from data providers and data management
software), due diligence (including third party diligence software),
(ii) compensation, fees and expenses paid to “Retained Domain Experts” for specialized services
(other than retainers and similar fees), to the extent not paid by prospective or actual portfolio
companies,
(iii) filing and similar fees paid on behalf of the Fund,
(iv) transaction expenses of the Fund, including such expenses with respect to transactions that
are not consummated by the Fund to the extent not reimbursed by portfolio companies
(including expenses that would have been borne by co-investors or co-investment vehicles),
(v) all custody, transfer, registration and similar expenses incurred by the Fund,
(vi) all brokerage, sale, and finder’s fees and commissions and discounts incurred in connection
with the purchase or sale of securities,
(vii) all premiums for insurance covering indemnified persons of the Fund, including insurance of
which the Firm and its affiliates are beneficiaries, cyber-security insurance premiums, and any
liability and errors and omissions insurance premiums,
(viii) all expenses of the Advisory Committee,
(ix) all expenses of the Social Impact Committee,
(x) all expenses incurred in connection with Partner meetings,
(xi) all interest on borrowed funds of the Fund and bridge financing expenses, financing,
commitment, origination and similar fees and expenses,
(xii) all extraordinary expenses of the Fund including all litigation and indemnification expenses,
(xiii) risk management assessment expenses and expenses associated with the Fund’s compliance
with applicable laws and regulations, including expenses incurred in connection with
complying with provisions of side letters (including “most favored nation” provisions), and
(xiv) all taxes and similar fees and expenses of the Fund (other than any taxes imposed on the Fund
under the Partnership Audit Rules, as defined below, that are allocable to a Partner of the
Fund),
(xv) Portfolio Fees (see Item 8 for more information), and
(xvi) Fees for additional legal, regulatory, tax, accounting, administration and similar services
provided to the Fund by the Firm and/or an affiliate (see Item 8 for more information).
Travel expenses may include, without limitation, expenses for business class travel as well as meals and
entertainment. Expenses of the types borne by the Fund but associated with any Feeder Fund organized to
facilitate the participation of certain investors in the Fund (including, without limitation, expenses of accounting
and tax services) may be borne by the Fund.
The Fund does not have its own separate employees or offices, and it does not reimburse the Firm for salaries
or office rent. The Firm is responsible for all of its overhead expenses and other similar expenses, except as
provided for herein.
The fee and expense description in this Brochure does not purport to be complete or comprehensive and
investors should refer to the Governing Documents for a more robust explanation.
D. Typically, the Management Fee is paid quarterly in advance. The Carried Interest, to the extent such
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2023) [Brochure] |
|---|
Types of Clients Adjuvant provides investment advisory services to pooled investment vehicles that are each excepted from the definition of an investment company under the Investment Company Act. As discussed in Item 4, interests in the Fund are and will be offered privately and generally available only to persons who are “accredited investors” as defined in Regulation D under the Securities Act and “qualified purchasers” as defined in Section 2(a)(51) of the Investment Company Act. The minimum initial capital commitment is $5,000,000, subject to reduction in the sole discretion of the General Partner. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Adjuvant Global Health Technology Fund de LP | [2020-03-10] | 48.2 M | 29.1 M |
| Offered $48,226,950 · Filed 2021-02-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Adjuvant Global Health Technology Fund LP | [2019-05-13] | 251.8 M | 152.4 M |
| Offered $251,773,050 · Filed 2021-02-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 268.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 268.0 |
| By Discretionary | ||
| Discretionary | 2 | 268.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 268.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 225.6 | |
| United States Persons | 42.5 | |
| Total | 2 | 268.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Jenny Yip | Executive Officer | 9 | 2 | |
| Glenn Rockman | Executive Officer | 6 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 4 | [0001935084] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Adjuvant Capital Management LLC | |
| Adjuvant Global Health Technology Fund LP | |
| Adjuvant Capital GP LP | |
| Adjuvant Global Health Technology Fund DE LP | |
| AN2 Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2024-01-16 | Sell | 84,093 | $19.65 | 1,652,427 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2024-01-16 | Sell | 15,907 | $19.65 | 312,573 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-11-14 | Sell | 288 | $16.15 | 4,651 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-11-14 | Sell | 1,522 | $16.15 | 24,580 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-10-02 | Sell | 4,770 | $16.07 | 76,654 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-10-02 | Sell | 902 | $16.07 | 14,495 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-29 | Sell | 15,764 | $16.28 | 256,638 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-29 | Sell | 83,337 | $16.28 | 1,356,726 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-28 | Sell | 7,160 | $16.11 | 115,348 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-28 | Sell | 1,356 | $16.11 | 21,845 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-27 | Sell | 707 | $16.07 | 11,361 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-27 | Sell | 134 | $16.07 | 2,153 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-13 | Sell | 64 | $16.00 | 1,024 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-13 | Sell | 336 | $16.00 | 5,376 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-07 | Sell | 2,841 | $16.05 | 45,598 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-07 | Sell | 537 | $16.05 | 8,619 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-06 | Sell | 598 | $16.02 | 9,580 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-09-06 | Sell | 3,164 | $16.02 | 50,687 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-08-23 | Sell | 336 | $16.00 | 5,376 |
|
AN2 Therapeutics Inc ANTX
Common Stock
|
2023-08-23 | Sell | 64 | $16.00 | 1,024 |
| showing 20 of 22 most recent transactions | |||||